LAVAL, QUEBEC, CANADA (MARCH 12, 2025) — Corealis Pharma, a leading contract development and manufacturing organization (CDMO) specializing in oral solid dosage formulations, is excited to announce the appointment of David Leroux-Petersen as its new Chief Executive Officer, following the retirement of founder and president, Dr. Yves Roy.
An Enduring Legacy of Leadership and Solid Science
For more than twenty years, Yves Roy has dedicated his career to creating healthier lives through a distinguished career in the healthcare, toxicology, and biopharmaceutical industries. In his early career, Yves Roy made a name for himself very quickly by introducing new services and emerging technologies to support R&D. He soon found himself in several high-profile management positions in major pharma companies.
When he cofounded Corealis in 2005, Yves Roy was able to use his unique expertise to overcome many challenges that pharmaceutical startups face. Over the years, he helped secure Corealis’s sterling reputation, not only as a reliable drug development partner, but also as a competitive advantage for biotechs hoping to minimize the risks and costs that typically accompany drug development. His dedication to the company’s mission, people, and culture are hallmarks of his success.
Yves Roy states:
“It has been an extraordinary honor to lead Corealis Pharma from its inception to becoming a trusted partner in the development of oral solid dosage products. I am confident that under David’s leadership, our clients and our team will be in excellent hands.”
A Renewed Commitment To Pharmaceutical Innovation
David Leroux-Petersen brings a wealth of drug development and executive leadership experience in the pharmaceutical and biotechnology sectors. Most recently, he served as corporate vice president at Charles River Laboratories, where he has led as Commercial Head, the manufacturing division that encompasses CDMO businesses, biologics testing, and microbial solutions.
His track record of implementing effective commercial strategies, launching innovative product lines, and building inclusive, high-performance teams aligns perfectly with Corealis Pharma’s future ambitions — including its ongoing laboratory expansion.
“I am thrilled to join Corealis Pharma at this exciting time,” David Leroux-Petersen states. “The company has built an impressive reputation for scientific excellence, high-quality delivery, and client satisfaction, and I look forward to building upon this strong foundation to drive future growth while maintaining the company’s core values and client-centric approach.”
What This Means for Clients and Stakeholders
To ensure a smooth transition, Dr. Roy will continue to support Corealis as a senior strategic advisor.
Clients that have returned to Corealis again and again will also find that, in addition to an alignment with Corealis’s goals, David Leroux-Petersen is aligned with its approach to partnership, including:
- A client-first focus
- Continuous innovation
- Collaboration and teamwork
In other words, Corealis will always be the partner that doesn’t over-promise and underdeliver, and the partner that would rather lose a project than risk damaging a relationship.
About Corealis
Corealis Pharma Inc. (“Corealis”) is a world-class formulation development company founded in 2005 by three leading scientists. We provide a complete line of services in formulation development and clinical supplies manufacturing of pharmaceutical oral solid dosage forms. We help small and medium-sized pharmaceutical specialty and biotech companies succeed with innovative strategies, state-of-the-art technologies, and value-added expertise. Corealis’s goal is to provide phase-appropriate trial materials to shorten the drug development cycle times and ensure a seamless transition to drug commercialization, in turn accelerating access to ground-breaking patient therapies. Learn more at CorealisPharma.com.
Follow us on social media:
Media Contact
Patrick Frankham, PhD, MBA
Dir. Développement des affaires / Dir. Business Development
patrick.frankham@corealispharma.com
M: (514) 943-1899
T: (450) 973-7505
Contact Corealis
Corealis’ experts are ready to answer any queries about the company’s oral solid dose offering, including its development and manufacturing capabilities.
